TY - JOUR
AU1 - Harvey, Raymond A.
AU2 - Rassen, Jeremy A.
AU3 - Kabelac, Carly A.
AU4 - Turenne, Wendy
AU5 - Leonard, Sandy
AU6 - Klesh, Reyna
AU7 - Meyer, William A.
AU8 - Kaufman, Harvey W.
AU9 - Anderson, Steve
AU1 - Cohen, Oren
AU1 - Petkov, Valentina I.
AU1 - Cronin, Kathy A.
AU1 - Van Dyke, Alison L.
AU1 - Lowy, Douglas R.
AU1 - Sharpless, Norman E.
AU1 - Penberthy, Lynne T.
AB - 
Key PointsQuestionCan observational clinical data from commercial laboratories be used to evaluate the comparative risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection for individuals who are antibody positive vs those who are antibody negative?
FindingIn this cohort study of more than 3.2 million US patients with a SARS-CoV-2 antibody test, 0.3% of those indexed with positive test results had evidence of a positive nucleic acid amplification test beyond 90 days after index, compared with 3.0% indexed with negative antibody test results.
MeaningIndividuals who are seropositive for SARS-CoV-2 based on commercial assays may be at decreased future risk of SARS-CoV-2 infection.

TI - Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection
JF - JAMA Internal Medicine
DO - 10.1001/jamainternmed.2021.0366
DA - 2021-05-24
UR - https://www.deepdyve.com/lp/american-medical-association/association-of-sars-cov-2-seropositive-antibody-test-with-risk-of-27UuCU2k4v
SP - 672
EP - 679
VL - 181
IS - 5
DP - DeepDyve
ER -